BF
ADMS

BOK Financial’s Adamas Pharmaceuticals ADMS Stock Holding History

BOK Financial’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,434
Closed -$189K – 955
2018
Q3 		$189K Sell
9,434
-18,687
-66% -$439K ﹤0.01% 881
2018
Q2 		$727K Buy
28,121
+10,651
+61% +$295K 0.02% 561
2018
Q1 		$417K Buy
+17,470
New +$551K 0.01% 679

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

BOK Financial's ADMS Position: Q4 2018 in Review

BOK Financial sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 9,434 shares — an estimated $189K sold.

BOK Financial first reported a position in ADMS in Q1 2018 and held it in 3 quarters. The position peaked at $727K in Q2 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • BOK Financial reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BOK Financial sold 9,434 Adamas Pharmaceuticals shares in Q4 2018, an estimated $189K.
  • BOK Financial first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • BOK Financial's Adamas Pharmaceuticals position peaked at $727K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on BOK Financial's 13F filing for Q4 2018, filed 13 Feb 2019.